Helus outlines Phase III HLP003 data and planned NDA filing
Helus said it expects top-line Phase III data for HLP003 in adjunctive MDD in Q4 2026 and targets an NDA filing in 2028, while also discussing progress in its neuropsychiatry pipeline.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.